Status:
COMPLETED
Evaluation of Accuracy of Continuous Glucose Monitoring (CGM) in Patients With End Stage Renal Disease (ESRD) on Intermittent Hemodialysis (iHD).
Lead Sponsor:
University of Virginia
Collaborating Sponsors:
DexCom, Inc.
Conditions:
Diabetes
Diabetes Mellitus, Type 1
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Recent advances in continuous glucose monitors (CGMs) and availability of commercial CGM products to patients with type 1 and type 2 diabetes has made the use of CGM more widespread. CGMs work by plac...
Detailed Description
Recent advances in continuous glucose monitors (CGMs) and availability of commercial CGM products to patients with type 1 and type 2 diabetes has made the use of CGM more widespread (1). CGMs work by ...
Eligibility Criteria
Inclusion
- Ages 18+
- Type 1 diabetes mellitus on intermittent HD thrice weekly OR Type 2 diabetes mellitus on intermittent HD thrice weekly
- Willingness and ability to comply with scheduled visits and study procedures
Exclusion
- Inability to comply with finger stick blood glucoses at least four times daily
- Noncompliant with HD therapies
- Pregnant women
Key Trial Info
Start Date :
February 19 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 29 2021
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04094064
Start Date
February 19 2020
End Date
September 29 2021
Last Update
December 21 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Meaghan Stumpf, MD
Charlottesville, Virginia, United States, 22903